Buy Pathogenetic Role of Aberrant Promoter Methylation in Lung Cancer
close menu
Bookswagon
search
My Account
Home > Medicine & Health Science textbooks > Medicine: general issues > Pathogenetic Role of Aberrant Promoter Methylation in Lung Cancer
Pathogenetic Role of Aberrant Promoter Methylation in Lung Cancer

Pathogenetic Role of Aberrant Promoter Methylation in Lung Cancer


     0     
5
4
3
2
1



Out of Stock


Notify me when this book is in stock
X
About the Book

This dissertation, "Pathogenetic Role of Aberrant Promoter Methylation in Lung Cancer" by Ching, Eunice, Chan, 陳清, was obtained from The University of Hong Kong (Pokfulam, Hong Kong) and is being sold pursuant to Creative Commons: Attribution 3.0 Hong Kong License. The content of this dissertation has not been altered in any way. We have altered the formatting in order to facilitate the ease of printing and reading of the dissertation. All rights not granted by the above license are retained by the author. Abstract: Abstract of thesis entitled Pathogenetic Role of Aberrant Promoter Methylation in Lung Cancer Submitted by Chan Ching, Eunice For the Degree of Doctor of Philosophy at the University of Hong Kong in May 2007 Lung cancer is the leading cause of cancer death in the United States and worldwide. Despite the improvement of diagnostic techniques and the understanding of molecular biology of lung cancers in recent years, the 5-year survival rate has remained poor. Epigenetic silencing of gene expression by promoter CpG islands is a common phenomenon in cancers. The detection of aberrant promoter methylation using methylation-specific PCR (MSP) of tumor suppressor genes has been proposed to be a potential screening approach for the early detection of lung cancers. The patterns of aberrant gene methylation of the genes CDKN2A, RARβ, DAP kinase and MGMT in non-small cell lung cancer (NSCLC) of 75 (44 adenocarcinomas and 31 squamous cell carcinomas, SCC) Chinese patients and its iuse in detecting cancer cells in 68 BAL samples of patients with suspected lung cancer were studied. Significantly more females had adenocarcinomas than SCC. Aberrant methylation in at least one gene was found in 63 of 75 (84%) NSCLCs. Females with NSCLC showed more frequent CDKN2A methylation (92%) than males and this frequency was one of the highest known. The frequency of RARβ methylation was 71%, which was considerably higher than that in Western patients; whereas DAP kinase and MGMT were methylated at frequencies of 35% and 15% respectively. From the cytology negative and MSP positive results in the BAL samples, 35 out of 41 were eventually shown to have malignant lung lesions, suggesting that MSP of a panel of genes might be a useful biomarker for the detection of lung cancer. Polymorphisms of genes involved in detoxification of carcinogens and modulating or repairing DNA damage after carcinogen exposure have been linked to the risks of lung cancer. The effect of polymorphism of GSTM1, GSTP1, MPO, XRCC1, and NQO1 genes on lung cancer risk was examined. In male patients, GSTM1 null genotype, the MPO wildtype G allele and the XRCC1 26304 C→T allele were found to be associated with an apparent reduced risk of lung cancer. The -463 G allele of MPO wildtype was significantly associated with an increased risk of iiCDKN2A methylation. The XRCC1 26304 C→T was significantly associated with CDKN2A and RARβ methylation. In female patients, GSTP1 2627 A→G polymorphism was significantly associated with lung cancer and the AG/GG genotype of GSTP1 2627 was significantly associated with CDKN2A and RARβ aberrant methylation. These results showed that functional deficiencies in metabolic pathways that protect cells from carcinogen induced DNA damage might be linked to aberrant promoter methylation of the CDKN2A and RARβ genes during lung carcinogenesis. Aberrant activation of the Wnt signalling is associated with carcinogenesis and other degenerative diseases. Both sFRP1 and WIF-1 are Wnt antagonists and high frequencies (82-94%) of aberrant promoter methylated were reported in both genes in lung cancers. sFRP1 and WIF-1 genes were aberrantly methylated in lung cancer cell lines, corresponding to suppressed gene expression. De-methylation and re-expression of sFRP1 and WIF-1 was achieved by treatment with 5-azacytidine. iii DOI: 10.5353/th_b3955781 Subjects: Lungs - Cancer


Best Sellers


Product Details
  • ISBN-13: 9781374663381
  • Publisher: Open Dissertation Press
  • Publisher Imprint: Open Dissertation Press
  • Height: 279 mm
  • No of Pages: 190
  • Weight: 454 gr
  • ISBN-10: 1374663387
  • Publisher Date: 27 Jan 2017
  • Binding: Paperback
  • Language: English
  • Spine Width: 10 mm
  • Width: 216 mm


Similar Products

Add Photo
Add Photo

Customer Reviews

REVIEWS      0     
Click Here To Be The First to Review this Product
Pathogenetic Role of Aberrant Promoter Methylation in Lung Cancer
Open Dissertation Press -
Pathogenetic Role of Aberrant Promoter Methylation in Lung Cancer
Writing guidlines
We want to publish your review, so please:
  • keep your review on the product. Review's that defame author's character will be rejected.
  • Keep your review focused on the product.
  • Avoid writing about customer service. contact us instead if you have issue requiring immediate attention.
  • Refrain from mentioning competitors or the specific price you paid for the product.
  • Do not include any personally identifiable information, such as full names.

Pathogenetic Role of Aberrant Promoter Methylation in Lung Cancer

Required fields are marked with *

Review Title*
Review
    Add Photo Add up to 6 photos
    Would you recommend this product to a friend?
    Tag this Book Read more
    Does your review contain spoilers?
    What type of reader best describes you?
    I agree to the terms & conditions
    You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.

    CUSTOMER RATINGS AND REVIEWS AND QUESTIONS AND ANSWERS TERMS OF USE

    These Terms of Use govern your conduct associated with the Customer Ratings and Reviews and/or Questions and Answers service offered by Bookswagon (the "CRR Service").


    By submitting any content to Bookswagon, you guarantee that:
    • You are the sole author and owner of the intellectual property rights in the content;
    • All "moral rights" that you may have in such content have been voluntarily waived by you;
    • All content that you post is accurate;
    • You are at least 13 years old;
    • Use of the content you supply does not violate these Terms of Use and will not cause injury to any person or entity.
    You further agree that you may not submit any content:
    • That is known by you to be false, inaccurate or misleading;
    • That infringes any third party's copyright, patent, trademark, trade secret or other proprietary rights or rights of publicity or privacy;
    • That violates any law, statute, ordinance or regulation (including, but not limited to, those governing, consumer protection, unfair competition, anti-discrimination or false advertising);
    • That is, or may reasonably be considered to be, defamatory, libelous, hateful, racially or religiously biased or offensive, unlawfully threatening or unlawfully harassing to any individual, partnership or corporation;
    • For which you were compensated or granted any consideration by any unapproved third party;
    • That includes any information that references other websites, addresses, email addresses, contact information or phone numbers;
    • That contains any computer viruses, worms or other potentially damaging computer programs or files.
    You agree to indemnify and hold Bookswagon (and its officers, directors, agents, subsidiaries, joint ventures, employees and third-party service providers, including but not limited to Bazaarvoice, Inc.), harmless from all claims, demands, and damages (actual and consequential) of every kind and nature, known and unknown including reasonable attorneys' fees, arising out of a breach of your representations and warranties set forth above, or your violation of any law or the rights of a third party.


    For any content that you submit, you grant Bookswagon a perpetual, irrevocable, royalty-free, transferable right and license to use, copy, modify, delete in its entirety, adapt, publish, translate, create derivative works from and/or sell, transfer, and/or distribute such content and/or incorporate such content into any form, medium or technology throughout the world without compensation to you. Additionally,  Bookswagon may transfer or share any personal information that you submit with its third-party service providers, including but not limited to Bazaarvoice, Inc. in accordance with  Privacy Policy


    All content that you submit may be used at Bookswagon's sole discretion. Bookswagon reserves the right to change, condense, withhold publication, remove or delete any content on Bookswagon's website that Bookswagon deems, in its sole discretion, to violate the content guidelines or any other provision of these Terms of Use.  Bookswagon does not guarantee that you will have any recourse through Bookswagon to edit or delete any content you have submitted. Ratings and written comments are generally posted within two to four business days. However, Bookswagon reserves the right to remove or to refuse to post any submission to the extent authorized by law. You acknowledge that you, not Bookswagon, are responsible for the contents of your submission. None of the content that you submit shall be subject to any obligation of confidence on the part of Bookswagon, its agents, subsidiaries, affiliates, partners or third party service providers (including but not limited to Bazaarvoice, Inc.)and their respective directors, officers and employees.

    Accept

    Fresh on the Shelf


    Inspired by your browsing history


    Your review has been submitted!

    You've already reviewed this product!
    Your IP: 216.73.216.43 IN